Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Present status and upcoming prospects of hedgehog pathway inhibitors in small cell lung cancer therapy.

Naqvi SH, Naqvi SH, Bandukda MY, Naqvi SM.

Infect Agent Cancer. 2013 May 22;8(1):17. doi: 10.1186/1750-9378-8-17.

2.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
3.

Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers.

De Smaele E, Ferretti E, Gulino A.

Curr Opin Investig Drugs. 2010 Jun;11(6):707-18. Review.

PMID:
20496266
4.

Targeted therapy for advanced Basal-cell carcinoma: vismodegib and beyond.

Cowey CL.

Dermatol Ther (Heidelb). 2013 Mar 2;3(1):17-31. doi: 10.1007/s13555-013-0019-9.

5.

A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.

Erdem GU, Sendur MA, Ozdemir NY, Yazıcı O, Zengin N.

Curr Med Res Opin. 2015 Apr;31(4):743-56. doi: 10.1185/03007995.2015.1018988. Review.

PMID:
25690490
6.

Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.

Cirrone F, Harris CS.

Clin Ther. 2012 Oct;34(10):2039-50. doi: 10.1016/j.clinthera.2012.08.011. Review.

PMID:
23036338
7.

Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.

Piérard-Franchimont C, Hermanns-Lê T, Paquet P, Herfs M, Delvenne P, Piérard GE.

Future Oncol. 2015 Nov;11(22):2997-3002. doi: 10.2217/fon.15.181. Review.

PMID:
26437034
8.

Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia.

Katagiri S, Tauchi T, Okabe S, Minami Y, Kimura S, Maekawa T, Naoe T, Ohyashiki K.

Clin Cancer Res. 2013 Mar 15;19(6):1422-32. doi: 10.1158/1078-0432.CCR-12-1777.

9.

Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.

Dessinioti C, Plaka M, Stratigos AJ.

Future Oncol. 2014 May;10(6):927-36. doi: 10.2217/fon.14.50.

PMID:
24941979
10.

The use of bevacizumab in non-small cell lung cancer: an update.

Lauro S, Onesti CE, Righini R, Marchetti P.

Anticancer Res. 2014 Apr;34(4):1537-45. Review. Erratum in: Anticancer Res. 2014 Jun;34(6):3232.

PMID:
24692680
11.

Hedgehog signaling pathway as a therapeutic target for ovarian cancer.

Li H, Li J, Feng L.

Cancer Epidemiol. 2016 Feb;40:152-7. doi: 10.1016/j.canep.2015.11.014. Review.

PMID:
26724464
12.

The dawn of hedgehog inhibitors: Vismodegib.

Sandhiya S, Melvin G, Kumar SS, Dkhar SA.

J Pharmacol Pharmacother. 2013 Jan;4(1):4-7. doi: 10.4103/0976-500X.107628.

13.
14.

Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.

Proctor AE, Thompson LA, O'Bryant CL.

Ann Pharmacother. 2014 Jan;48(1):99-106. doi: 10.1177/1060028013506696. Review.

PMID:
24259609
15.

Hedgehog signaling pathway and gastric cancer.

Katoh Y, Katoh M.

Cancer Biol Ther. 2005 Oct;4(10):1050-4. Review.

PMID:
16258256
16.

Inhibition of hedgehog/Gli signaling by botanicals: a review of compounds with potential hedgehog pathway inhibitory activities.

Drenkhahn SK, Jackson GA, Slusarz A, Starkey NJ, Lubahn DB.

Curr Cancer Drug Targets. 2013 Jun;13(5):580-95. Review.

PMID:
23675897
18.
19.

Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations.

Galimberti F, Busch AM, Chinyengetere F, Ma T, Sekula D, Memoli VA, Dragnev KH, Liu F, Johnson KC, Guo Y, Freemantle SJ, Andrew AS, Greninger P, Robbins DJ, Settleman J, Benes C, Dmitrovsky E.

Int J Oncol. 2012 Nov;41(5):1751-61. doi: 10.3892/ijo.2012.1599.

20.

Supplemental Content

Support Center